These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 9205774

  • 1. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
    Kometani M, Hayashi N, Yamamoto S, Nakao K, Inukai T.
    Arzneimittelforschung; 1997 May; 47(5):613-9. PubMed ID: 9205774
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
    Yamamoto S, Hayashi N, Kometani M, Nakao K, Inukai T.
    Arzneimittelforschung; 1997 May; 47(5):604-12. PubMed ID: 9205773
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
    Hayashi N, Fujimura Y, Yamamoto S, Kometani M, Nakao K.
    Arzneimittelforschung; 1997 May; 47(5):625-9. PubMed ID: 9205776
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs.
    Hayashi N, Yamamoto S, Kometani M, Nakao K.
    Arzneimittelforschung; 1997 May; 47(5):620-5. PubMed ID: 9205775
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 5th communication: hemodynamic effects of valsartan in dog heart failure models.
    Yamamoto S, Hayashi N, Kometani M, Nakao K.
    Arzneimittelforschung; 1997 May; 47(5):630-4. PubMed ID: 9205777
    [Abstract] [Full Text] [Related]

  • 6. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction.
    de Gasparo M, Hess P, Nuesslein-Hildesheim B, Bruneval P, Clozel JP.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):151-8. PubMed ID: 11967807
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
    Lassila M, Davis BJ, Allen TJ, Burrell LM, Cooper ME, Cao Z.
    Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
    [Abstract] [Full Text] [Related]

  • 8. Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model.
    Ledingham JM, Laverty R.
    Clin Exp Pharmacol Physiol; 2005 Apr; 32(1-2):76-85. PubMed ID: 15730439
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term blockade of the angiotensin II receptor in renin transgenic rats, salt-loaded Dahl rats, and stroke-prone spontaneously hypertensive rats.
    Stasch JP, Knorr A, Hirth-Dietrich C, Krämer T, Hübsch W, Dressel J, Fey P, Beuck M, Sander E, Frobel K, Kazda S.
    Arzneimittelforschung; 1997 Sep; 47(9):1016-23. PubMed ID: 9342414
    [Abstract] [Full Text] [Related]

  • 11. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats.
    Stier CT, Adler LA, Levine S, Chander PN.
    J Hypertens Suppl; 1993 Apr; 11(3):S37-42. PubMed ID: 8315518
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
    Gottdiener JS.
    Circulation; 1999 Aug 10; 100(6):685-6. PubMed ID: 10490345
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K, Minatoguchi S, Ito Y, Hukunishi M, Matsuno Y, Kakami M, Kawasaki M, Nishigaki K, Takemura G, Fujiwara H.
    Hypertens Res; 2007 Apr 10; 30(4):307-13. PubMed ID: 17541209
    [Abstract] [Full Text] [Related]

  • 19. Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
    Ke YS, Cao H, Yang T.
    Acta Pharmacol Sin; 2000 Nov 10; 21(11):1043-7. PubMed ID: 11501062
    [Abstract] [Full Text] [Related]

  • 20. Influence of Valsartan on myocardial apoptosis in spontaneously hypertensive rats.
    Li W, Sun N, Liu W, Chen Y, Yu Y.
    Chin Med J (Engl); 2002 Mar 10; 115(3):364-6. PubMed ID: 11940365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.